KROS Stock Summary and Trading Ideas (Keros Therapeutics | NASDAQ:KROS)

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Keros Therapeutics trades on the NASDAQ stock market under the symbol KROS.

As of January 2, 2026, KROS stock price declined to $18.78 with 311,314 million shares trading.

KROS has a beta of 0.40, meaning it tends to be less sensitive to market movements. KROS has a correlation of 0.01 to the broad based SPY ETF.

KROS has a market cap of $571.64 million. This is considered a Small Cap stock.

Last quarter Keros Therapeutics reported $14 million in Revenue and -$.18 earnings per share. This beat revenue expectation by $9 million and exceeded earnings estimates by $.82.

In the last 3 years, KROS traded as high as $73.00 and as low as $9.12.

The top ETF exchange traded funds that KROS belongs to (by Net Assets): IWM, VTI, XBI, IWN, VXF.

KROS has outperformed the market in the last year with a return of +18.6%, while the SPY ETF gained +17.8%. In the last 3 month period, KROS beat the market returning +18.7%, while SPY returned +2.8%. However, in the most recent 2 weeks KROS has underperformed the stock market by returning -9.8%, while SPY returned +2.0%.

KROS support price is $19.68 and resistance is $21.04 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KROS shares will trade within this expected range on the day.